Table 2: Treatment Data
Parameter Parameter ICI +SBRT (n=16) ICI (n=5)
ICI / ICI and SBRT given as what line of therapy (n) Mean, range 4+1.8; 2-8 4+1.4; 2-5
Cycles ICI given Mean, range 7.25; 2-22 6.2; 2-14
SBRT Dose (n) 35 Gy in 5 fractions 1 NA
30 Gy in 5 fractions 9
27.5 Gy in 5 fractions 1
27 Gy in 3 fractions 2
25 Gy in 5 fractions 1
18 Gy in 1-3 fractions 2
Average PFS from 2nd line treatment onward Mean, Range 4+1.8; 2-8 8.6+6.2; 3-17
Average PFS on intervention Mean, Range 4.1+4; 1.2-14 8.6+6.2; 3-17
Best one-month response (RANO) CR 0 0
PR 2 0
SD 8 2
PD 6 3
6-month PFS (n) Progressed 13 4
Stable 3 1
OS after intervention (months) Mean, Range 7.75+2.9; 4-16 13.8+15; 2-38
Adverse Events (CTCAE) Grade 1 5 4
Grade 2 1 0
Grade >3 0 0
Steroids (n) Yes 12 3
No 4 2
Bevacizumab (n) Yes 6 1
No 10 4
Abbreviations: ICI: immune checkpoint inhibition; Gy: Gray; SBRT: stereotactic body radiation therapy; PFS: progression-free survival; OS: overall survival: RANO: Response assessment in neuro-oncology; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CTCAE: Common Terminology Criteria for Adverse Events; NA: not applicable Abbreviations: ICI: immune checkpoint inhibition; Gy: Gray; SBRT: stereotactic body radiation therapy; PFS: progression-free survival; OS: overall survival: RANO: Response assessment in neuro-oncology; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CTCAE: Common Terminology Criteria for Adverse Events; NA: not applicable Abbreviations: ICI: immune checkpoint inhibition; Gy: Gray; SBRT: stereotactic body radiation therapy; PFS: progression-free survival; OS: overall survival: RANO: Response assessment in neuro-oncology; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CTCAE: Common Terminology Criteria for Adverse Events; NA: not applicable Abbreviations: ICI: immune checkpoint inhibition; Gy: Gray; SBRT: stereotactic body radiation therapy; PFS: progression-free survival; OS: overall survival: RANO: Response assessment in neuro-oncology; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CTCAE: Common Terminology Criteria for Adverse Events; NA: not applicable